A heterogeneous catalytic method for the conversion of nitriles into amides using molecular sieves modified with copper(II)
摘要:
A heterogenous catalytic method is developed for the hydration of nitriles into amides with acetaldoxime. Copper(II) supported on 4 angstrom molecular sieves is an efficient catalyst for this reaction. (C) 2011 Elsevier Ltd. All rights reserved.
Acetamides and benzamides that are useful in treating sexual dysfunction
申请人:——
公开号:US20040029887A1
公开(公告)日:2004-02-12
The present invention relates to the use of compounds of formula (I)
1
for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
本发明涉及使用式(I)的化合物治疗性功能障碍,以及含有式(I)化合物的组合物用于治疗性功能障碍。
Novel amides useful for treating pain
申请人:Zheng Zhu Guo
公开号:US20050080095A1
公开(公告)日:2005-04-14
The present invention relates to compounds of formula (I-VII)
or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R
6
, R
7
and R
8
are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.
[EN] NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS DE SHP2
申请人:JACOBIO PHARMACEUTICALS CO LTD
公开号:WO2020063760A1
公开(公告)日:2020-04-02
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.
Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R
1
-R
3
R
6c
and X
1
are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treating diseases mediated by the CCR5 receptor.